Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroleptic malignant syndrome and methylphenidate

H Ehara1, Y Maegaki, K Takeshita

  • 1Division of Child Neurology, Institute of Neurological Sciences, Tottori University Faculty of Medicine, Yonago, Japan.

Pediatric Neurology
|November 27, 1998
PubMed
Summary

Neuroleptic malignant syndrome (NMS) in a child was possibly caused by methylphenidate, a stimulant medication. Brain injury from perinatal hypoxia may predispose patients to this rare adverse drug reaction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft.

Clinical nephrology·2009
Same author

[Rupture of intrascrotal epidermoid cyst complicated by bacterial infection: a case report].

Hinyokika kiyo. Acta urologica Japonica·2001
Same author

Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages.

International immunopharmacology·2001
Same author

Schizencephaly in triple-X syndrome.

Pediatrics international : official journal of the Japan Pediatric Society·2001
Same author

Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Effects of hypercapnia and hypocapnia on [Ca2+]i mobilization in human pulmonary artery endothelial cells.

Journal of applied physiology (Bethesda, Md. : 1985)·2001

Area of Science:

  • Pediatric Neurology
  • Pharmacology
  • Neuroscience

Background:

  • Neuroleptic malignant syndrome (NMS) is a rare but serious adverse reaction to neuroleptic medications.
  • The exact pathogenesis of NMS is not fully understood but is generally attributed to dopaminergic blockade.
  • Methylphenidate, a central nervous system stimulant, is typically used to treat attention deficit hyperactivity disorder.

Observation:

  • A 1-year-old female presented with symptoms consistent with NMS.
  • The patient had a history of severe perinatal hypoxic-ischemic encephalopathy, resulting in supratentorial brain defects.
  • Methylphenidate was identified as the probable causative agent for the NMS episode.

Findings:

  • This case suggests a potential link between methylphenidate and NMS, challenging the traditional dopaminergic blockade hypothesis.

Related Experiment Videos

  • The mechanism may involve a relative gamma-aminobutyric acid-ergic deficiency, as indicated by the efficacy of diazepam.
  • Methylphenidate's action as a dopamine agonist, inhibiting dopamine reuptake, might influence NMS pathogenesis differently than typical neuroleptics.

    • Implications:

    • This report highlights the importance of considering NMS in patients on methylphenidate, especially those with pre-existing neurological conditions.
    • Further research is needed to elucidate the specific mechanisms underlying methylphenidate-induced NMS.
    • Understanding atypical NMS presentations can improve diagnosis and management in pediatric populations.